Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Sclerostin and Cardiovascular Disease

25 Jul 2023

Abstract excerpt

PURPOSE OF REVIEW: The role of wnt signalling in atherogenesis raises the possibility that the wnt inhibitor, sclerostin, provides a natural defence to this process, and that anti-sclerostin antibodies might increase the risk of atherosclerosis and associated conditions such as CVD. This article aims to triangulate evidence concerning possible adverse effects of sclerostin inhibition on CVD risk. RECENT FINDINGS:...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Protease and Inhibitor Mechanisms
Share to Cell Adhesion Molecules Research
Share to Protein Kinase Regulation and GTPase Signaling

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 37490188
DOI: 10.1007/s11914-023-00810-w

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Sclerostin and Cardiovascular DiseasePMID 37490188Read ↗

Role of Sclerostin in Cardiovascular SystemSemantic proximity Read ↗

Lifelong genetically lowered sclerostin and risk of cardiovascular diseaseSemantic proximity Read ↗

The cause-effect relationship between sclerostin levels, cardiovascular biomarkers, risk factors, and cardiovascular diseaseSemantic proximity Read ↗

Lowering of circulating sclerostin may increase risk of atherosclerosis and its risk factors: evidence from a genome-wide association meta-analysis followed by Mendelian randomizationSemantic proximity Read ↗

Lowering of Circulating Sclerostin May Increase Risk of Atherosclerosis and Its Risk Factors: Evidence From a Genome-Wide Association Meta-Analysis Followed by Mendelian Randomization.Semantic proximity Read ↗

Observational and Mendelian randomization studies of plasma sclerostin levels do not provide evidence of cardiovascular adverse effects of sclerostin inhibition.Semantic proximity Read ↗

Effect of genetically predicted sclerostin on cardiovascular biomarkers, risk factors, and disease outcomes.Semantic proximity Read ↗

Wnt Signaling Pathway Inhibitor Sclerostin Inhibits Angiotensin II-Induced Aortic Aneurysm and Atherosclerosis.Semantic proximity Read ↗

Genetic and atherosclerotic plaque immunohistochemical analyses do not associate reduced sclerostin expression with cardiovascular eventsSemantic proximity Read ↗

Sclerostin Downregulation Globally by Naturally Occurring Genetic Variants, or Locally in Atherosclerotic Plaques, Does Not Associate With Cardiovascular Events in HumansSemantic proximity Read ↗

The Role of Sclerostin in Bone DiseasesSemantic proximity Read ↗

Endocrine functions of sclerostinSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.